Abstract
Introduction
Osimertinib is an EGFR inhibitor licensed for the treatment of EGFR-mutant, T790M-positive
NSCLC. Previously unreported, frequent transient asymptomatic pulmonary opacities
were noted in patients during osimertinib therapy at the University of Colorado.
Methods
Computed tomography imaging and clinical notes on patients with NSCLC who had been
treated with osimertinib at the University of Colorado were retrospectively reviewed.
Results
Transient asymptomatic pulmonary opacities developed in seven of 20 patients (35%)
while they were receiving osimertinib. The radiological patterns seen included ground-glass
opacities with or without nodular consolidation. The median time to development of
the first lesion was 8.7 weeks (range 1.6–43 weeks), the median time to resolution
during continued osimertinib was 6 weeks (range 1–11 weeks).
Conclusions
Transient asymptomatic pulmonary opacities may be a previously unrecognized, benign
feature associated with osimertinib therapy that may be mistaken for isolated pulmonary
progression or the beginning of more severe pneumonitis. If new-onset pulmonary lesions,
especially those associated with ground-glass appearances, are asymptomatic and localized
and there is no evidence of disease progression elsewhere, it may be reasonable to
continue treatment with osimertinib and monitor the lesions for resolution.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Thoracic OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Pulmonary toxicities of gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.Medicine (Baltimore). 2016; 95: e3008
- FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.Oncologist. 2003; 8: 303-306
- An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.Am J Respir Crit Care Med. 2013; 188: 733-748
- Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?.Lung Cancer. 2014; 83: 383-388
- Interstitial lung disease associated with drug therapy.Br J Cancer. 2004; 91: S18-S23
- AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.N Engl J Med. 2015; 372: 1689-1699
- AZD9291-induced acute interstitial lung disease.Chin Med J. 2016; 129: 1507-1508
Article info
Publication history
Published online: September 09, 2016
Accepted:
August 28,
2016
Received in revised form:
August 25,
2016
Received:
August 5,
2016
Footnotes
Disclosure: The authors declare no conflict of interest.
Identification
Copyright
© 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
